The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Big medtechs’ efficiency starts to recover from Covid
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
AHA 2022 – History repeats for Medtronic
The company’s renal denervation system has failed in a crucial late-stage trial, just as an earlier version did eight years ago.
J&J enlivens the medtech merger scene
Buying Abiomed for $17bn sharpens the group’s focus, somewhat unexpectedly, on cardiovascular tech.
Thermo Fisher flashes the Covid cash
The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.
